Syncona was bringing pioneering gene therapy research from Oxford University into a new business tackling inherited retinal diseases that cause blindness.

The challenge was to turn complex science into a compelling human proposition.

The positioning and name, Beacon Therapeutics, captured the ambition to restore sight, creating a new biotechnology brand that launched with £96 million in funding.